Trial Profile
Multimodal Therapy With and Without Cetuximab in Patients With Locally Advanced Esophageal Carcinoma - An Open-Label Phase III Trial.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Docetaxel
- Indications Adenocarcinoma; Adenosquamous carcinoma; Carcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 05 Oct 2022 Results of long term follow up assessing the pattern of disease recurrence and subsequent therapies in patients with recurrent oesophageal cancer based on prospectively collected data within a predefined subproject, published in the European Journal of Cancer.
- 01 Jun 2022 Results assessing impact of surgical technique in regard to morbidity and mortality after neoadjuvant treatment for esophageal cancer. published in the Annals of Surgery.
- 26 Feb 2019 This trial has been completed in Germany, according to European Clinical Trials Database.